Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
292 0 |
SM ISO690:2012 MAKATSARIYA, Alexander, SLUKHANCHUK, Ekaterina, BITSADZE, Viktoriya Omarovna, KHIZROEVA, Jamilya, TRETYAKOVA, Maria, SHKODA, A., ELALAMY, Ismail, DI RENZO, Gian Carlo, RIZZO, Giuseppe, PYATIGORSKAYA, N., SOLOPOVA, A., GRIGOREVA, Kristina, NAKAIDZE, I., MITRYUK, Diana. The effect of various types of anticoagulant therapy on the reduction of mortality in COVID-19. In: Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, nr. 3(76), pp. 268-278. ISSN 0869-6047. DOI: https://doi.org/10.15690/vramn1551 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk | ||
Numărul 3(76) / 2021 / ISSN 0869-6047 | ||
|
||
DOI:https://doi.org/10.15690/vramn1551 | ||
Pag. 268-278 | ||
Rezumat | ||
Coronavirus disease 2019 (COVID-19) is a viral infection that, in severe course, leads to the development of a cytokine storm, systemic inflammatory response and coagulopathy. Unlike other sepsis-associated disseminated intravascular coagulopathy, COVID-19 induced coagulopathy is realized mainly in thrombosis. Researchers around the world are currently developing adequate diagnostic, monitoring and anticoagulant therapy approaches to safely and effectively manage patients with severe COVID-19. The need to develop laboratory monitoring is due to the fact that 20% of patients have changes in hemostasis indicators, while in patients with a severe form of the disease, they are present in 100% of cases. In case of deaths from COVID-19, there is an increase in the concentration of D-dimer and fibrinogen degradation products. Thus, the severity of hemostasis disorders has an important prognostic value. Anticoagulant therapy is included in the list of all recommendations as an effective means of reducing mortality from COVID-19. The questions of the recommended groups and doses of anticoagulant drugs are still open. The approach to the choice of an anticoagulant should be based not only on risk factors, characteristics of the course of the disease, anamnesis, but also on the wishes of the patient during long-term therapy at the post-hospital stage. |
||
Cuvinte-cheie Anticoagulants, COVID-19, Direct-acting oral anticoagulants, Low-molecular-weight heparin, thrombosis, антикоагулянты, COVID-19, тромбозы, низкомолекулярные гепарины, прямые оральные антикоагулянты |
||
|
Google Scholar Export
<meta name="citation_title" content="The effect of various types of anticoagulant therapy on the reduction of mortality in COVID-19"> <meta name="citation_author" content="Makatsariya Alexander"> <meta name="citation_author" content="Slukhanchuk Ekaterina"> <meta name="citation_author" content="Bitsadze Viktoriya Omarovna"> <meta name="citation_author" content="Khizroeva Jamilya"> <meta name="citation_author" content="Tretyakova Maria"> <meta name="citation_author" content="Shkoda A."> <meta name="citation_author" content="Elalamy Ismail"> <meta name="citation_author" content="Di Renzo Gian Carlo"> <meta name="citation_author" content="Rizzo Giuseppe"> <meta name="citation_author" content="Pyatigorskaya N."> <meta name="citation_author" content="Solopova A."> <meta name="citation_author" content="Grigoreva Kristina"> <meta name="citation_author" content="Nakaidze I."> <meta name="citation_author" content="Mitryuk Diana"> <meta name="citation_publication_date" content="2021/03/01"> <meta name="citation_journal_title" content="Vestnik Rossiiskoi Akademii Meditsinskikh Nauk"> <meta name="citation_volume" content="76"> <meta name="citation_issue" content="3"> <meta name="citation_firstpage" content="268"> <meta name="citation_lastpage" content="278"> <meta name="citation_pdf_url" content="https://vestnikramn.spr-journal.ru/jour/article/view/1551">